Document is current
Any future updates will be listed below
-
Authors
Oñate, Guadalupe https://orcid.org/0000-0003-2180-2371
Pratcorona, Marta
Garrido, Ana
Artigas-Baleri, Alicia
Bataller, Alex
Tormo, Mar https://orcid.org/0000-0001-9622-1649
Arnan, Montserrat
Vives, Susana
Coll, Rosa
Salamero, Olga https://orcid.org/0000-0003-3237-0025
Vall-Llovera, Ferran
Sampol, Antònia https://orcid.org/0000-0001-7465-6203
Garcia, Antoni
Cervera, Marta
Avila, Sara Garcia
Bargay, Joan
Ortín, Xavier
Nomdedéu, Josep F. https://orcid.org/0000-0003-3399-346X
Esteve, Jordi https://orcid.org/0000-0002-8056-648X
Sierra, Jorge https://orcid.org/0000-0002-7966-0356
,
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI17/01246)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI20/01621)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CM20/00061)
Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (SGR-Cat 2021)
- License Information
-
More Information
Article History
Received: 10 February 2023
Revised: 5 April 2023
Accepted: 13 April 2023
First Online: 5 May 2023
Conflict of interest
: JS reports personal fees from AbbVie, Vyxeos, Gilead, CSL Behring, Astellas, and Gilead; grants and personal fees from Novartis and Daiichi-Sankyo; and grants from Amgen and Jazz Pharmaceuticals. JE reports consultancy-honoraria from Abbvie, Novartis, Astellas, Jazz Pharmaceuticals, BMS-Celgene, Pfizer, Daichii-Sankyo and research grants from Novartis and Jazz Pharmaceuticals. The remaining authors declare no competing financial interests.
